Weekly Combined Oral Contraceptive
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Lyndra Therapeutics, Massachusetts Institute of Technology
Details
- API: Levonorgestrel, Ethinyl Estradiol
- Target: Progesterone Receptor, Estrogen Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Regimen: 1 Pill/Week
- MPT: Not Potential MPT
- Promising Attributes: A weekly pill has the potential to improve adherence. Pills are a user-friendly delivery form but many users struggle with daily medication.
Product Status
While development was funded through 2024, there are no public updates or publications and the developer is inactive as of March 2025.
History
2018: Lyndra receives Gates Foundation funding to support the development of a combined oral contraceptive taken weekly.